An observational study in Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8 and Stage I Bladder Cancer AJCC v8, sponsored by Mayo Clinic. Active, not recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-17.
Sponsored by Mayo Clinic · Observational
This study evaluates the effect of bladder cancer treatment on quality of life.
PRIMARY OBJECTIVES:
I. To compare general and disease-specific quality of life outcomes at 6, 12, 24, and 36 months after treatment for localized bladder cancer using the PROMIS-29 and the Bladder Cancer Index (BCI) respectively.
II. To identify patient level characteristics that may influence quality of life outcomes after treatment for localized bladder cancer.
OUTLINE: This is an observational study.
Patients complete surveys and also have their medical records reviewed on study.
1,616 studies on the registry are indexed under Urinary Bladder Neoplasms; 421 are open to participants now.
This study's enrollment of 204 is above the median of 180 across 374 observational studies indexed under Urinary Bladder Neoplasms.
Browse Urinary Bladder Neoplasms studies →Mayo Clinic is the lead sponsor of 3,218 studies on the registry; 670 are open to participants now.
Of its 445 completed or terminated interventional studies of FDA-regulated products, 313 (70%) have results posted.
Counted across the registry records on this site, refreshed daily.
Men and women diagnosed with clinically localized bladder cancer
Exclusion Criteria:
Patients complete surveys and also have their medical records reviewed on study.
Other: Non-Interventional Study
Non-Interventional Study
Change in quality of life outcomes - PROMIS-29
Assessed using the Patient-Reported Outcomes Measurement Information System (PROMIS)-29, a 29-item instrument with 29 questions in eight categories of Health Related Quality of Life (HRQOL): physical function, sleep disturbance, pain interference and pain intensity, fatigue, anxiety, depression) and ability to participate in social roles and activities. Questions are answered on a 5-point scale with varying responses assigned to the scale based on the category/question.
Time frame: At baseline, 6, 12, 24, and 36 months
Change in quality of life outcomes - Bladder Cancer Index
Assessed using the Bladder Cancer Index (BCI). The BCI consists of 36 items, with 4- or 5-point Likert response scales for each item, covering 3 primary domains: urinary (14 items), bowel (10 items), and sexual (12 items). The items focus on the frequency of the disease symptoms, with answer scales such as: "Never, rarely, about half the time, usually, or always".
Time frame: At baseline, 6, 12, 24, and 36 months
Patient level characteristics
Will be assessed by the effect of race/ethnicity, comorbid conditions, education level, gender, and age on patient reported outcomes. Interactions between intervention type and patient-level characteristics will be included. The distributions of variables will be summarized graphically and numerically.
Time frame: At baseline, 6, 12, 24, and 36 months after treatment
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Mayo Clinic